White House shift on psychedelics positive for NRx, says D. Boral

D. Boral Capital analyst Jason Kolbert says NRx Pharmaceuticals (NRXP) is advancing a ketamine-based therapeutic strategy at a time when U.S. policy toward psychedelic drugs is “undergoing a meaningful shift.” While ketamine is not classified as a traditional psychedelic, its mechanistic overlap and positioning within the broader neuropsychiatric landscape “places it squarely within the current policy debate,” the analyst tells investors in a research note. D. Boral says recent White House actions aimed at accelerating research and access to psychedelic therapies could represent an incremental tailwind for companies like NRx. The firm has a Buy rating on the shares with a $34 price target